FMR1 and the Continuum of Primary Ovarian Insufficiency

ABSTRACT

Spontaneous 46,XX primary ovarian insufficiency (POI) is a term that describes ovarian dysfunction resulting in a range of abnormalities, from infertility to early menopause as the end stage (overt POI). The most common known genetic cause of 46,XX POI is the expansion of a CGG repeat to 55 to 199 copies in the 5′ untranslated region in the X-linked FMR1 gene. This “premutation” is associated with overt POI (FXPOI) in ~20% of carrier women. Greater than 200 CGG copies results in methylation of the CGG repeats and subsequent silencing of the FMR1 gene, causing fragile X syndrome. This “full” mutation is not associated with FXPOI. Even in the absence of overt FXPOI, women who carry the premutation may exhibit ovarian dysfunction along a continuum of severity. Evidence also suggests that the severity of FXPOI depends on the CGG repeat length, background modifier genes, and environmental factors (e.g., smoking). This review explores the range of ovarian dysfunction, the mechanisms behind the dysfunction, and the reasons for the variability in presentation in women who carry the FMR1 premutation. Understanding the mechanisms responsible for development of FXPOI is paramount to providing these women with the best overall health care.

KEYWORDS

Primary ovarian insufficiency - premature ovarian failure - fragile X syndrome - Fragile X Mental Retardation 1 (FMR1) gene

REFERENCES

• 1 Nelson L M. Clinical practice. Primary ovarian insufficiency.  N Engl J Med. 2009;  360 (6) 606-614
• 2 Hubayter Z R, Popat V, Vanderhoof V H et al.. A prospective evaluation of antral follicle function in women with 46,XX spontaneous primary ovarian insufficiency.  Fertil Steril. 2010;  94 (5) 1769-1774
• 3 Gallagher J C. Effect of early menopause on bone mineral density and fractures.  Menopause. 2007;  14 (3 Pt 2) 567-571
• 4 Jacobsen B K, Knutsen S F, Fraser G E. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study.  J Clin Epidemiol. 1999;  52 (4) 303-307
• 5 Mondul A M, Rodriguez C, Jacobs E J, Calle E E. Age at natural menopause and cause-specific mortality.  Am J Epidemiol. 2005;  162 (11) 1089-1097
• 6 Popat V B, Calis K A, Vanderhoof V H et al.. Bone mineral density in estrogen-deficient young women.  J Clin Endocrinol Metab. 2009;  94 (7) 2277-2283
• 7 Allingham-Hawkins D J, Babul-Hirji R, Chitayat D et al.. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study—preliminary data.  Am J Med Genet. 1999;  83 (4) 322-325
• 8 Sherman S L. Premature ovarian failure in the fragile X syndrome.  Am J Med Genet. 2000;  97 (3) 189-194
• 9 Sherman S T. FMR1 premutation: a leading cause of inherited ovarian dysfunction. In: Arrieta I, Penagarikano O, Télez M, eds. Fragile Sites: New Discoveries and Changing Perspectives. Hauppauge, NY: Nova Science Publishers; 2007: 299-320
• 10 Crawford D C, Acuña J M, Sherman S L. FMR1 and the fragile X syndrome: human genome epidemiology review.  Genet Med. 2001;  3 (5) 359-371
• 11 Cronister A, Teicher J, Rohlfs E M, Donnenfeld A, Hallam S. Prevalence and instability of fragile X alleles: implications for offering fragile X prenatal diagnosis.  Obstet Gynecol. 2008;  111 (3) 596-601
• 12 Allen E G, Sullivan A K, Marcus M et al.. Examination of reproductive aging milestones among women who carry the FMR1 premutation.  Hum Reprod. 2007;  22 (8) 2142-2152
• 13 Hundscheid R D, Braat D D, Kiemeney L A, Smits A P, Thomas C M. Increased serum FSH in female fragile X premutation carriers with either regular menstrual cycles or on oral contraceptives.  Hum Reprod. 2001;  16 (3) 457-462
• 14 Murray A, Webb J, MacSwiney F, Shipley E L, Morton N E, Conway G S. Serum concentrations of follicle stimulating hormone may predict premature ovarian failure in FRAXA premutation women.  Hum Reprod. 1999;  14 (5) 1217-1218
• 15 Rohr J, Allen E G, Charen K et al.. Anti-Mullerian hormone indicates early ovarian decline in fragile X mental retardation (FMR1) premutation carriers: a preliminary study.  Hum Reprod. 2008;  23 (5) 1220-1225
• 16 Welt C K, Smith P C, Taylor A E. Evidence of early ovarian aging in fragile X premutation carriers.  J Clin Endocrinol Metab. 2004;  89 (9) 4569-4574
• 17 Murray A, Ennis S, MacSwiney F, Webb J, Morton N E. Reproductive and menstrual history of females with fragile X expansions.  Eur J Hum Genet. 2000;  8 (4) 247-252
• 18 Sullivan A K, Marcus M, Epstein M P et al.. Association of FMR1 repeat size with ovarian dysfunction.  Hum Reprod. 2005;  20 (2) 402-412
• 19 Bell M V, Hirst M C, Nakahori Y et al.. Physical mapping across the fragile X: hypermethylation and clinical expression of the fragile X syndrome.  Cell. 1991;  64 (4) 861-866
• 20 Sutcliffe J S, Nelson D L, Zhang F et al.. DNA methylation represses FMR-1 transcription in fragile X syndrome.  Hum Mol Genet. 1992;  1 (6) 397-400
• 21 Tassone F, Hagerman P J. Expression of the FMR1 gene.  Cytogenet Genome Res. 2003;  100 (1–4) 124-128
• 22 Sherman S, Pletcher B A, Driscoll DACINGMN. Fragile X syndrome: diagnostic and carrier testing.  Genet Med. 2005;  7 (8) 584-587
• 23 Fernandez-Carvajal I, Lopez Posadas B, Pan R, Raske C, Hagerman P J, Tassone F. Expansion of an FMR1 grey-zone allele to a full mutation in two generations.  J Mol Diagn. 2009;  11 (4) 306-310
• 24 Terracciano A, Pomponi M G, Marino G M et al.. Expansion to full mutation of a FMR1 intermediate allele over two generations.  Eur J Hum Genet. 2004;  12 (4) 333-336
• 25 Allen E G, He W, Yadav-Shah M, Sherman S L. A study of the distributional characteristics of FMR1 transcript levels in 238 individuals.  Hum Genet. 2004;  114 (5) 439-447
• 26 García-Alegría E, Ibáñez B, Mínguez M et al.. Analysis of FMR1 gene expression in female premutation carriers using robust segmented linear regression models.  RNA. 2007;  13 (5) 756-762
• 27 Kenneson A, Zhang F, Hagedorn C H, Warren S T. Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers.  Hum Mol Genet. 2001;  10 (14) 1449-1454
• 28 Tassone F, Beilina A, Carosi C et al.. Elevated FMR1 mRNA in premutation carriers is due to increased transcription.  RNA. 2007;  13 (4) 555-562
• 29 Tassone F, Hagerman R J, Taylor A K, Gane L W, Godfrey T E, Hagerman P J. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome.  Am J Hum Genet. 2000;  66 (1) 6-15
• 30 Tassone F, Hagerman R J, Taylor A K et al.. Clinical involvement and protein expression in individuals with the FMR1 premutation.  Am J Med Genet. 2000;  91 (2) 144-152
• 31 Peprah E, He W, Allen E, Oliver T, Boyne A, Sherman S L. Examination of FMR1 transcript and protein levels among 74 premutation carriers.  J Hum Genet. 2010;  55 (1) 66-68
• 32 Hundscheid R D, Smits A P, Thomas C M, Kiemeney L A, Braat D D. Female carriers of fragile X premutations have no increased risk for additional diseases other than premature ovarian failure.  Am J Med Genet A. 2003;  117A (1) 6-9
• 33 Hagerman P J, Greco C M, Hagerman R J. A cerebellar tremor/ataxia syndrome among fragile X premutation carriers.  Cytogenet Genome Res. 2003;  100 (1-4) 206-212
• 34 Lambalk C B, De Koning C H, Braat D D. The endocrinology of dizygotic twinning in the human.  Mol Cell Endocrinol. 1998;  145 (1–2) 97-102
• 35 Fryns J P. The female and the fragile X. A study of 144 obligate female carriers.  Am J Med Genet. 1986;  23 (1–2) 157-169
• 36 Turner G, Robinson H, Wake S, Martin N. Dizygous twinning and premature menopause in fragile X syndrome.  Lancet. 1994;  344 (8935) 1500
• 37 Vianna-Morgante A M, Costa S S. Premature ovarian failure is associated with maternally and paternally inherited premutation in Brazilian families with fragile X.  Am J Hum Genet. 2000;  67 (1) 254-255 author reply 256-258
• 38 Sherman S L, Meadows K L, Ashley A E. Examination of factors that influence the expansion of the fragile X mutation in a sample of conceptuses from known carrier females.  Am J Med Genet. 1996;  64 (2) 256-260
• 39 Ennis S, Ward D, Murray A. Nonlinear association between CGG repeat number and age of menopause in FMR1 premutation carriers.  Eur J Hum Genet. 2006;  14 (2) 253-255
• 40 Tejada M I, García-Alegría E, Bilbao A et al.. Analysis of the molecular parameters that could predict the risk of manifesting premature ovarian failure in female premutation carriers of fragile X syndrome.  Menopause. 2008;  15 (5) 945-949
• 41 Bodega B, Bione S, Dalprà L et al.. Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation.  Hum Reprod. 2006;  21 (4) 952-957
• 42 Bretherick K L, Fluker M R, Robinson W P. FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure.  Hum Genet. 2005;  117 (4) 376-382
• 43 Gleicher N, Weghofer A, Oktay K, Barad D H. Correlation of triple repeats on the FMR1 (fragile X) gene to ovarian reserve: a new infertility test?.  Acta Obstet Gynecol Scand. 2009;  88 (9) 1024-1030
• 44 Streuli I, Fraisse T, Ibecheole V, Moix I, Morris M A, de Ziegler D. Intermediate and premutation FMR1 alleles in women with occult primary ovarian insufficiency.  Fertil Steril. 2009;  92 (2) 464-470
• 45 Bennett C E, Conway G S, Macpherson J N, Jacobs P A, Murray A. Intermediate sized CGG repeats are not a common cause of idiopathic premature ovarian failure.  Hum Reprod. 2010;  25 (5) 1335-1338
• 46 Loesch D Z, Khaniani M S, Slater H R et al.. Small CGG repeat expansion alleles of FMR1 gene are associated with parkinsonism.  Clin Genet. 2009;  76 (5) 471-476
• 47 Kraff J, Tang H T, Cilia R et al.. Screen for excess FMR1 premutation alleles among males with parkinsonism.  Arch Neurol. 2007;  64 (7) 1002-1006
• 48 Kurz M W, Schlitter A M, Klenk Y et al.. FMR1 alleles in Parkinson's disease: relation to cognitive decline and hallucinations, a longitudinal study.  J Geriatr Psychiatry Neurol. 2007;  20 (2) 89-92
• 49 Toft M, Aasly J, Bisceglio G et al.. Parkinsonism, FXTAS, and FMR1 premutations.  Mov Disord. 2005;  20 (2) 230-233
• 50 Jin P, Zarnescu D C, Zhang F et al.. RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in Drosophila.  Neuron. 2003;  39 (5) 739-747
• 51 Willemsen R, Hoogeveen-Westerveld M, Reis S et al.. The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome.  Hum Mol Genet. 2003;  12 (9) 949-959
• 52 Todd P K, Paulson H L. RNA-mediated neurodegeneration in repeat expansion disorders.  Ann Neurol. 2010;  67 (3) 291-300
• 53 Brouwer J R, Huizer K, Severijnen L A et al.. CGG-repeat length and neuropathological and molecular correlates in a mouse model for fragile X-associated tremor/ataxia syndrome.  J Neurochem. 2008;  107 (6) 1671-1682
• 54 Loesch D Z, Bui Q M, Huggins R M, Mitchell R J, Hagerman R J, Tassone F. Transcript levels of the intermediate size or grey zone fragile X mental retardation 1 alleles are raised, and correlate with the number of CGG repeats.  J Med Genet. 2007;  44 (3) 200-204
• 55 Nolin S L, Brown W T, Glicksman A et al.. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles.  Am J Hum Genet. 2003;  72 (2) 454-464
• 56 Zhong N, Yang W, Dobkin C, Brown WTCINAJHGJ. Fragile X gene instability: anchoring AGGs and linked microsatellites.  Am J Hum Genet. 1995;  57 (2) 351-361
• 57 Weisman-Shomer P, Cohen E, Fry M. Interruption of the fragile X syndrome expanded sequence d(CGG)(n) by interspersed d(AGG) trinucleotides diminishes the formation and stability of d(CGG)(n) tetrahelical structures.  Nucleic Acids Res. 2000;  28 (7) 1535-1541
• 58 Napierala M, Michalowski D, de Mezer M, Krzyzosiak W J. Facile FMR1 mRNA structure regulation by interruptions in CGG repeats.  Nucleic Acids Res. 2005;  33 (2) 451-463
• 59 Bione S, Benedetti S, Goegan M et al.. Skewed X-chromosome inactivation is not associated with premature ovarian failure in a large cohort of Italian patients.  Am J Med Genet A. 2006;  140 (12) 1349-1351
• 60 Spath M A, Nillesen W N, Smits A P et al.. X chromosome inactivation does not define the development of premature ovarian failure in fragile X premutation carriers.  Am J Med Genet A. 2010;  152A (2) 387-393
• 61 Rodriguez-Revenga L, Madrigal I, Badenas C, Xunclà M, Jiménez L, Milà M. Premature ovarian failure and fragile X female premutation carriers: no evidence for a skewed X-chromosome inactivation pattern.  Menopause. 2009;  16 (5) 944-949
• 62 Hundscheid R D, Sistermans E A, Thomas C M et al.. Imprinting effect in premature ovarian failure confined to paternally inherited fragile X premutations.  Am J Hum Genet. 2000;  66 (2) 413-418
• 63 Tassone F, Hagerman R J, Chamberlain W D, Hagerman P J. Transcription of the FMR1 gene in individuals with fragile X syndrome.  Am J Med Genet. 2000;  97 (3) 195-203
• 64 Hunter J E, Epstein M P, Tinker S W, Charen K H, Sherman S L. Fragile X-associated primary ovarian insufficiency: evidence for additional genetic contributions to severity.  Genet Epidemiol. 2008;  32 (6) 553-559
• 65 Miano M G, Laperuta C, Chiurazzi P, D'Urso M, Ursini M V. Ovarian dysfunction and FMR1 alleles in a large Italian family with POF and FRAXA disorders: case report.  BMC Med Genet. 2007;  8 18
• 66 Bontekoe C J, Bakker C E, Nieuwenhuizen I M et al.. Instability of a (CGG)98 repeat in the Fmr1 promoter.  Hum Mol Genet. 2001;  10 (16) 1693-1699
• 67 Entezam A, Biacsi R, Orrison B et al.. Regional FMRP deficits and large repeat expansions into the full mutation range in a new fragile X premutation mouse model.  Gene. 2007;  395 (1-2) 125-134
• 68 Peier A M, Nelson D L. Instability of a premutation-sized CGG repeat in FMR1 YAC transgenic mice.  Genomics. 2002;  80 (4) 423-432